193 related articles for article (PubMed ID: 26421390)
1. Juvenile dystonia-parkinsonism syndrome caused by a novel p.S941Tfs1X ATP13A2 (PARK9) mutation.
Martino D; Melzi V; Franco G; Kandasamy N; Monfrini E; Di Fonzo A
Parkinsonism Relat Disord; 2015 Nov; 21(11):1378-80. PubMed ID: 26421390
[No Abstract] [Full Text] [Related]
2. Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation.
Crosiers D; Ceulemans B; Meeus B; Nuytemans K; Pals P; Van Broeckhoven C; Cras P; Theuns J
Parkinsonism Relat Disord; 2011 Feb; 17(2):135-8. PubMed ID: 21094623
[No Abstract] [Full Text] [Related]
3. Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation.
Inzelberg R; Estrada-Cuzcano A; Laitman Y; De Vriendt E; Friedman E; Jordanova A
J Parkinsons Dis; 2018; 8(3):399-403. PubMed ID: 29966207
[TBL] [Abstract][Full Text] [Related]
4. From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations.
Erro R; Picillo M; Manara R; Pellecchia MT; Barone P
Parkinsonism Relat Disord; 2019 Aug; 65():272-273. PubMed ID: 31151786
[No Abstract] [Full Text] [Related]
5. Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome.
Pietrzak A; Badura-Stronka M; Kangas-Kontio T; Felczak P; Kozubski W; Latos-Bielenska A; Wierzba-Bobrowicz T; Florczak-Wyspianska J
Folia Neuropathol; 2019; 57(3):285-294. PubMed ID: 31588715
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism.
Park JS; Mehta P; Cooper AA; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM
Hum Mutat; 2011 Aug; 32(8):956-64. PubMed ID: 21542062
[TBL] [Abstract][Full Text] [Related]
7. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
Park JS; Sue CM
Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
[TBL] [Abstract][Full Text] [Related]
8. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9).
Eiberg H; Hansen L; Korbo L; Nielsen IM; Svenstrup K; Bech S; Pinborg LH; Friberg L; Hjermind LE; Olsen OR; Nielsen JE
Clin Genet; 2012 Sep; 82(3):256-63. PubMed ID: 21696388
[TBL] [Abstract][Full Text] [Related]
9. Siblings with unusual presentation of early onset Parkinson's disease with dual heterozygous PARK2 and PARK 9 mutation.
Chatterjee K; Choudhury S; Shubham S; Mondal B; Basu P; Kumar H
Parkinsonism Relat Disord; 2018 Jul; 52():117-118. PubMed ID: 29606608
[No Abstract] [Full Text] [Related]
10. ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein.
Tsunemi T; Hamada K; Krainc D
J Neurosci; 2014 Nov; 34(46):15281-7. PubMed ID: 25392495
[TBL] [Abstract][Full Text] [Related]
11. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
[TBL] [Abstract][Full Text] [Related]
12. Ataxia-myoclonus syndrome due to a novel homozygous ATP13A2 mutation.
De Michele G; Galatolo D; Lieto M; Fico T; Saccà F; Santorelli FM; Filla A
Parkinsonism Relat Disord; 2020 Jul; 76():42-43. PubMed ID: 32559632
[No Abstract] [Full Text] [Related]
13. Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism.
Podhajska A; Musso A; Trancikova A; Stafa K; Moser R; Sonnay S; Glauser L; Moore DJ
PLoS One; 2012; 7(6):e39942. PubMed ID: 22768177
[TBL] [Abstract][Full Text] [Related]
14. Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation.
Lees AJ; Singleton AB
Neurology; 2007 May; 68(19):1553-4. PubMed ID: 17485640
[No Abstract] [Full Text] [Related]
15. Analysis of ATP13A2 in large neurodegeneration with brain iron accumulation (NBIA) and dystonia-parkinsonism cohorts.
Kruer MC; Paudel R; Wagoner W; Sanford L; Kara E; Gregory A; Foltynie T; Lees A; Bhatia K; Hardy J; Hayflick SJ; Houlden H
Neurosci Lett; 2012 Aug; 523(1):35-8. PubMed ID: 22743658
[TBL] [Abstract][Full Text] [Related]
16. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome.
Grünewald A; Arns B; Seibler P; Rakovic A; Münchau A; Ramirez A; Sue CM; Klein C
Neurobiol Aging; 2012 Aug; 33(8):1843.e1-7. PubMed ID: 22296644
[TBL] [Abstract][Full Text] [Related]
17. ATP13A2 novel mutations causing a rare form of juvenile-onset Parkinson disease.
Suleiman J; Hamwi N; El-Hattab AW
Brain Dev; 2018 Oct; 40(9):824-826. PubMed ID: 29903538
[TBL] [Abstract][Full Text] [Related]
18. Kufor Rakeb syndrome without gaze palsy and pyramidal signs due to novel ATP13A2 mutations.
Satolli S; Di Fonzo A; Zanobio M; Pezzullo G; De Micco R
Neurol Sci; 2023 Oct; 44(10):3723-3725. PubMed ID: 37306797
[No Abstract] [Full Text] [Related]
19. Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation.
Tsunemi T; Krainc D
Hum Mol Genet; 2014 Jun; 23(11):2791-801. PubMed ID: 24334770
[TBL] [Abstract][Full Text] [Related]
20. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease.
Di Fonzo A; Chien HF; Socal M; Giraudo S; Tassorelli C; Iliceto G; Fabbrini G; Marconi R; Fincati E; Abbruzzese G; Marini P; Squitieri F; Horstink MW; Montagna P; Libera AD; Stocchi F; Goldwurm S; Ferreira JJ; Meco G; Martignoni E; Lopiano L; Jardim LB; Oostra BA; Barbosa ER; ; Bonifati V
Neurology; 2007 May; 68(19):1557-62. PubMed ID: 17485642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
